Log in

Zynex Stock Price, Forecast & Analysis (OTCMKTS:ZYXI)

$9.26
+0.05 (+0.54 %)
(As of 11/17/2019 03:48 PM ET)
Today's Range
$9.11
Now: $9.26
$9.39
50-Day Range
$8.60
MA: $10.20
$12.51
52-Week Range
$2.58
Now: $9.26
$13.10
Volume162,559 shs
Average Volume232,397 shs
Market Capitalization$303.20 million
P/E Ratio42.09
Dividend YieldN/A
Beta1.05
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ZYXI
CUSIPN/A
Phone303-703-4906

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.43 million
Cash Flow$0.52 per share
Book Value$0.15 per share

Profitability

Net Income$7.36 million

Miscellaneous

EmployeesN/A
Market Cap$303.20 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ZYXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYXI and its competitors with MarketBeat's FREE daily newsletter.


Zynex (OTCMKTS:ZYXI) Frequently Asked Questions

What is Zynex's stock symbol?

Zynex trades on the OTCMKTS under the ticker symbol "ZYXI."

How were Zynex's earnings last quarter?

Zynex Inc. (OTCMKTS:ZYXI) released its quarterly earnings data on Tuesday, October, 29th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.00. The business had revenue of $11.82 million for the quarter, compared to analyst estimates of $11.06 million. Zynex had a return on equity of 152.81% and a net margin of 33.33%. View Zynex's Earnings History.

What price target have analysts set for ZYXI?

2 equities research analysts have issued 12-month price objectives for Zynex's stock. Their forecasts range from $12.00 to $12.00. On average, they anticipate Zynex's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 29.6% from the stock's current price. View Analyst Price Targets for Zynex.

What is the consensus analysts' recommendation for Zynex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zynex.

Has Zynex been receiving favorable news coverage?

Media headlines about ZYXI stock have trended extremely negative on Sunday, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zynex earned a news impact score of -5.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for Zynex.

Who are some of Zynex's key competitors?

What other stocks do shareholders of Zynex own?

Who are Zynex's key executives?

Zynex's management team includes the folowing people:
  • Mr. Thomas Sandgaard, Founder, Pres, CEO & Chairman (Age 60)
  • Mr. Daniel J. Moorhead, Chief Financial Officer (Age 47)
  • Mr. David B. Mogill, VP of Operations
  • Mr. Robert Bird, VP of Marketing
  • Mr. Steve Siefring, Director of Bus. Devel.

Who are Zynex's major shareholders?

Zynex's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Calamos Advisors LLC (0.84%), Cadence Capital Management LLC (0.76%), Russell Investments Group Ltd. (0.41%), Newman Dignan & Sheerar Inc. (0.10%), Hancock Whitney Corp (0.05%) and Mackay Shields LLC (0.04%). Company insiders that own Zynex stock include Daniel J Moorhead and Thomas Sandgaard. View Institutional Ownership Trends for Zynex.

Which major investors are selling Zynex stock?

ZYXI stock was sold by a variety of institutional investors in the last quarter, including Mackay Shields LLC and Newman Dignan & Sheerar Inc.. Company insiders that have sold Zynex company stock in the last year include Daniel J Moorhead and Thomas Sandgaard. View Insider Buying and Selling for Zynex.

Which major investors are buying Zynex stock?

ZYXI stock was acquired by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Cadence Capital Management LLC, Russell Investments Group Ltd., Hancock Whitney Corp, SRS Capital Advisors Inc. and Tower Research Capital LLC TRC . View Insider Buying and Selling for Zynex.

How do I buy shares of Zynex?

Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zynex's stock price today?

One share of ZYXI stock can currently be purchased for approximately $9.26.

How big of a company is Zynex?

Zynex has a market capitalization of $303.20 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis. View Additional Information About Zynex.

What is Zynex's official website?

The official website for Zynex is http://www.zynexmed.com/.

How can I contact Zynex?

Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected]


MarketBeat Community Rating for Zynex (OTCMKTS ZYXI)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  147 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  280
MarketBeat's community ratings are surveys of what our community members think about Zynex and other stocks. Vote "Outperform" if you believe ZYXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Featured Article: What is the G-20?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel